Literature DB >> 12917859

Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study.

Gerard E Francisco1, Corwin Boake.   

Abstract

OBJECTIVE: To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors.
DESIGN: Case series.
SETTING: Tertiary care center. PARTICIPANTS: Ten adults with poststroke hemiparesis who were ambulatory at the time of pump implantation.
INTERVENTIONS: Implantation of ITB pump after inadequate control of spasticity with other interventions. Time from stroke onset to implantation averaged 28.6 months (range, 9-55mo). MAIN OUTCOME MEASURES: Customary walking speed was measured from the time required to walk 50ft (15m) at a self-selected pace. Evaluators rated spastic hypertonia and functional mobility.
RESULTS: Statistically significant improvements occurred in walking speed, functional mobility ratings, and spasticity (P<.05) at a follow-up interval that averaged 8.9 months. Mean walking speed over 50ft improved from 36.6 to 52cm/s. Mean Modified Ashworth Scale scores in the muscles of the affected lower limb improved from 2.0 to 0.4. Normal muscle strength (5/5) was preserved in the unaffected limbs.
CONCLUSIONS: This preliminary study suggests that ITB therapy, in combination with physical therapy, may improve walking speed and functional mobility in ambulatory individuals with poststroke spastic hemiplegia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917859     DOI: 10.1016/s0003-9993(03)00134-5

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  11 in total

1.  [Intrathecal baclofen therapy in ambulatory patients with spastic hemiparesis following stroke. Short report of two cases].

Authors:  S Kästner
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

2.  Discovery of a Negative Allosteric Modulator of GABAB Receptors.

Authors:  Lin-Hai Chen; Bing Sun; Yang Zhang; Tong-Jie Xu; Zhi-Xiong Xia; Jian-Feng Liu; Fa-Jun Nan
Journal:  ACS Med Chem Lett       Date:  2014-05-27       Impact factor: 4.345

3.  Opisthotonus and intrathecal treatment with baclofen (ITB) in children.

Authors:  Berten Ceulemans; Johanna van Rhijn; Sandra Kenis; Ria Krols; Annick Laridon; Tony Van Havenbergh
Journal:  Eur J Pediatr       Date:  2007-08-24       Impact factor: 3.183

4.  Effects of serotonergic medications on locomotor performance in humans with incomplete spinal cord injury.

Authors:  Kristan A Leech; Catherine R Kinnaird; T George Hornby
Journal:  J Neurotrauma       Date:  2014-06-20       Impact factor: 5.269

Review 5.  Botulinum toxin in poststroke spasticity.

Authors:  Suheda Ozcakir; Koncuy Sivrioglu
Journal:  Clin Med Res       Date:  2007-06

6.  The efficacy of traditional Thai massage in decreasing spasticity in elderly stroke patients.

Authors:  Thanitta Thanakiatpinyo; Supakij Suwannatrai; Ueamphon Suwannatrai; Phanitanong Khumkaew; Dokmai Wiwattamongkol; Manmas Vannabhum; Somluck Pianmanakit; Vilai Kuptniratsaikul
Journal:  Clin Interv Aging       Date:  2014-08-11       Impact factor: 4.458

7.  Combined effect of botulinum toxin and splinting on motor components and function of people suffering a stroke.

Authors:  Malek Amini; Aryan Shamili; Bijan Frough; Marzieh Pashmdarfard; AbolGhasem Fallahzadeh Abarghouei
Journal:  Med J Islam Repub Iran       Date:  2016-05-21

8.  Ancillary benefits of bladder chemodenervation for SCI neurogenic bladder.

Authors:  Brandon M Haynes; Nathan C Osbun; Claire C Yang
Journal:  Spinal Cord Ser Cases       Date:  2018-09-11

9.  Pendulum test in chronic hemiplegic stroke population: additional ambulatory information beyond spasticity.

Authors:  Yin-Kai Dean Huang; Wei Li; Yi-Lin Chou; Erica Shih-Wei Hung; Jiunn-Horng Kang
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

Review 10.  Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity.

Authors:  Michelle Kaku; David M Simpson
Journal:  Drug Des Devel Ther       Date:  2016-03-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.